Written by: Jody Agena, PharmD, MBA, BCOP
Download Here

Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), a key component of the B-Cell receptor and cytokine receptor pathway.  BTK inhibition is vital for decreased malignant B-Cell proliferation and survival.  This molecule disrupts the proliferation of B-Cell cancers such as Mantle Cell Lymphoma, Chronic/Small Lymphocytic Leukemia, Marginal Zone Lymphoma, and Waldenstrom Macroglobulinemia. Managing both medication dosing and adverse effects are prime examples of key areas for additional intervention opportunities for improved patient health outcomes within the medically integrated team.

Continue reading Ibrutinib Management
Read More